Silymarin Inhibits the Progression of Fibrosis in the Early Stages of Liver Injury in CCl4-Treated Rats

다국어 초록 (Multilingual Abstract)

Liver fibrosis, a common condition occurring during the evolution of almost all chronic liver diseases, is the consequence of hepatocyte injury that leads to the activation of Kupffer cells and hepatic stellate cells (HSC). Silymarin (Si) is a herbal product widely used for its hepatoprotective potential. Our study aims to investigate the effects of two different doses of Silymarin on a CCl4-induced model of liver fibrosis with a focus on the early stages of liver injury. Fifty Wistar rats were randomly divided into five groups (n = 10): control group (sunflower oil twice a week); CMC group (carboxymethyl cellulose five times a week, sunflower oil twice a week); CCl4 group (CCl4 in sunflower oil, by gavage, twice a week); CCl4 + Si 50 group (CCl4 twice a week, Silymarin 50 mg/b.w. in CMC five times a week); and CCl4 + Si 200 group (similar to the previous group, with Si 200 mg/b.w.). One month after the experiment began we explored hepato-cytolysis (aminotransferases and lactate dehydrogenase), oxidative stress, fibrosis (histological score, hyaluronic acid), markers of HSC activation (transforming growth factor β1 [TGF-β1], and α-smooth muscle actin [α-SMA] expression by western blot) and activation of Kupffer cells by immunohistochemistry. Our data showed that Si 50 mg/b.w. had the capacity of reducing oxidative stress, hepato-cytolysis, fibrosis, activation of Kupffer cells, and the expression of a-SMA and TGF-β1 with better results than Si 200 mg/b.w. Thus, the usual therapeutic dose of Silymarin, administered in the early stages of fibrotic changes is capable of inhibiting the fibrogenetic mechanism and the progression of initial liver fibrosis.

참고문헌 (Reference)

1 Clichici S, "Transient oxidative stress and inflammation after intraperitoneal administration of multiwalled carbon nanotubes functionalized with single strand DNA in rats" 259 : 281-292, 2012

2 Nieto N, "Stimulation and proliferation of primary rat hepatic stellate cellsy cytochrome P450 2E1-derived reactive oxygen species" 35 : 62-73, 2002

3 Wellington K, "Silymarin: a review of its clinical properties in the management of hepatic disorders" 15 : 465-489, 2001

4 Kim M, "Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells" 30 : 473-479, 2012

5 Fe´her J, "Silymarin in the prevention and treatment of liver diseases and primary liver cancer" 13 : 210-217, 2012

6 Trappoliere M, "Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells" 50 : 1102-1111, 2009

7 Loguercio C, "Silybin and the liver: from basic research to clinical practice" 17 : 2288-2301, 2011

8 Malhi H, "Schiff’s Diseases of the liver, Vol.1" Lippincott Williams &Wilkins 313-324, 2007

9 Friedman SL, "Schiff’s Diseases of the Liver, Vol.1" Lippincott Williams &Wilkins 395-410, 2007

10 Muriel P, "Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid" 96 : 375-380, 2005

11 Nieto N, "Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells" 44 : 1487-1501, 2006

12 Lee KS, "Oxidative stress effect on the activation of hepatic stellate cells" 42 : 1-8, 2001

13 Reznick AZ, "Oxidative damage to proteins spectrophotometric method for carbonyl assay" 233 : 357-363, 1994

14 Bergmeyer HU, "Optimization of methods for aspartate aminotransferase and alanine aminotransferase" 24 : 58-73, 1978

15 Clichici S, "Noninvasive oxidative stress markers for liver fibrosis development in the evolution of toxic hepatitis" 98 : 195-204, 2011

16 Yeshua H, "Non invasive assessment of liver fibrosis" 13 : 5-11, 2008

17 Friedman SL, "Mac the knife? Macrophages-the double-edged sword of hepatic fibrosis" 115 : 29-32, 2005

18 Matsuzawa N, "Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet" 46 : 1392-1403, 2007

19 Krieg AF, "Lactate dehydrogenase isoenzymes a comparison of pyruvate-to-lactate and lactate-topyruvate assays" 13 : 196-203, 1967

20 Chin-Hui Su, "Increase of Phosphatase and Tensin Homolog by Silymarin to Inhibit Human Pharynx Squamous Cancer" 한국식품영양과학회 16 (16): 778-784, 2013

21 Paradis V, "In situ detection of lipid peroxidation in chronic hepatitis C:correlation with pathological features" 50 : 401-406, 1997

22 Conti M, "Improved fluorimetric determination of malondialdehyde" 37 : 1273-1275, 1991

23 Shafik AN, "Improved antifibrotic effect of a combination of verapamil and silymarin in rat-induced liver fibrosis" 12 : 143-149, 2011

24 Pradhan SC, "Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine" 124 : 491-504, 2006

25 Usha K, "Hepatoprotective effect of hygrophila spinosa and cassia occidentalis on carbon tetrachloride induced liver damage in experimental rats" 22 : 132-135, 2007

26 Chen IS, "Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis" 92 : 1441-1447, 2012

27 Urtasun R, "Hepatic stellate cells and oxidative stress" 99 : 2007

28 Olteanu D, "Hepatic and systemic effects of Rosuvastatin on an experimental model of bile duct ligation in rats" 63 : 483-496, 2012

29 Vats P, "Glutathione metabolism under high-altitude stress and effect of antioxidant supplementation" 79 : 1106-1111, 2008

30 Tsai JH, "Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats" 15 : 508-514, 2008

31 Loguercio C, "Del Vecchio Blanco C : Effect of silybin in patients with chronic hepatitis : preliminary results of a multicentre randomized contrlled trial vs placebo" 138 (138): 8800-, 2010

32 Shaker ME, "Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis" 670 : 593-600, 2011

33 Faouzi S, "Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway" 276 : 49077-49082, 2001

34 Ahmed AF, "Aminoguanidine potentiates the hepatoprotective effect of silymarin in CCL4 treated rats" 10 : 207-215, 2011

35 Bradford MM, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding" 72 : 248-254, 1976

36 Hui CK, "A comparison in the progression of liver fibrosis in chronic hepatitisCbetween persistently normal and elevated transaminase" 38 : 511-517, 2003